Real-time financial, economic, and global news with market-focused context and analysis.
Coverage spans equities, macroeconomic data, commodities, currencies, technology, politics, and global events—paired with analysis that highlights why each development matters for traders and investors. From breaking headlines to hourly market snapshots and in-depth articles, the News Hub is designed to help you stay informed, oriented, and ahead of market-moving events.
Broadcom ($AVGO) is a buy at $333.17 despite a downgraded internal forecast. The company generates roughly $39.4B of free cash flow, earns a 38% return on equity, and sits squarely in the AI infrastructure sweet spot. Valuation is rich (P/E ~42, EV/EBITDA ~31) but reasonable against the company's margins and cash returns. Entry $333.17, stop $300, …
Liberty Gold looks set to negotiate favorable funding terms this cycle. Management's focus on de-risking key Nevada assets, a modest cash runway, and a friendly gold-price backdrop create a scenario where a well-structured financing or JV could unlock re-rating. This is a directional long trade targeting that re-rating while risk-managing dilution …
Fastly looks like a tactically attractive long after a strong run this year. Record Q2 revenue, improving margins and growing AI/edge demand have the stock sitting on a reasonable play: buy near $22.42 with a mid-term horizon to capture re-rating catalysts and upside from partnerships and investor visibility.
Denifanstat's positive Phase 3 results in China de-risk the basic efficacy question for Sagimet's AURORA U.S. trial, turning the U.S. program into a replication exercise rather than a discovery event. With the stock trading at about $9.74 and a market cap near $690.7M, the risk-reward now favors a tactical short into the enrollment and initial scre…
Arcus Bio's casdatifan data have reignited optimism, but the stock is richly valued versus fundamentals and faces an imminent pivotal readout. This trade idea recommends a tactical long sized for volatility: entry at $23.75, stop at $19.50, and a target at $31.00 with a mid-term horizon tied to upcoming trial catalysts.
Natural Gas Services Group (NGS) is trading below many of its historical multiples after a pullback. With a market cap near $398M, an EV/EBITDA around 8.7x, and a rental-heavy business that benefits quickly from higher activity because of short contract tenors, NGS offers asymmetric upside if commodity and activity levels normalize. We upgrade to B…
Klarna trades at $13.24 with a market cap near $4.96B after a summer guidance cut and executive departures. Operational traction (120+ million shoppers, new merchant integrations) plus improving marketing ROI argue the sell-off overshot. This trade idea lays out a mid-term long with defined entry, stop and target and explains catalysts and risks th…
Berkshire Hathaway’s $930 million stake in Bending Spoons and an apparent tilt toward tech under CEO Greg Abel have introduced fresh narrative risk into a traditionally conservative conglomerate. At $540, BRK.B sits at its 52-week high with an overbought RSI and thin days-to-cover for shorts. This trade idea outlines a tactical put play to profit f…
Bristol-Myers Squibb ($BMY) screens cheap at ~13x earnings with $11.4B in free cash flow and a 4% dividend yield. Ahead of Q3 results, I see a favorable risk-reward for a mid-term bullish trade: entry $61.00, target $72.00, stop $56.50, horizon mid term (45 trading days). The upside case is earnings stability plus visible cash flow support for divi…
Fabrinet (FN) is trading well below its 52-week high after a Q4 beat that showed DCI revenue becoming the company's largest segment. With quarterly revenue momentum, a reasonable P/S near 2.7, and a pullback to $365.50, this is a structured long idea for investors who want exposure to AI-driven optical packaging at a discount — with clear entry, st…
SpaceX continues to deliver on the hard parts of aerospace: launch cadence, reusability, and a growing Starlink business. That combination provides asymmetric upside if growth monetizes, but execution and regulatory risk remain real. This trade recommends a tactical long with a clear entry, stop and target tied to near-term operational catalysts.
Viper Energy (VNOM) is a capital-light mineral and royalty owner that has been growing production and raising distributions while keeping a hedging framework that preserves oil-price upside. The combination of strong production growth, a chunky quarterly distribution ($0.67), and recent M&A makes VNOM an actionable long with a structured hedge. I r…
Brinker International (EAT) looks positioned to convert strong same-store sales momentum and analyst EPS upgrades into share-price upside. The stock trades at a modest multiple relative to growth, supported by $557.5M in free cash flow and a 52-week range that leaves room to the upside. I recommend a mid-term long with a clear entry, stop and targe…
Micron's fundamentals and cash generation justify a constructive upgrade. With free cash flow of $59B, EPS around $75, a low debt load and AI-driven memory demand still ramping, this is a trade worth initiating on weakness. Tactical entry, clear stop and a 180-trading-day target balance upside capture with cycle risk.
Royal Gold (RGLD) trades around $240 with a $20.2B market cap, low leverage and an attractive mix of income and optionality from gold, silver and copper streams. I view the stock as underpriced relative to its durable cash flow profile and downside protection; actionable plan below for a long trade over the next 180 trading days.
Unusual Machines (UMAC) is a small-cap supplier of FPV drone components sitting squarely at the intersection of consumer FPV demand and a sudden surge in U.S. government interest in domestic drone manufacturing. The name is richly valued on revenue today but shows attractive asymmetric upside if it captures government contracts or broad OEM adoptio…
Churchill Capital Corp XI is the SPAC vehicle set to bring Agility Robotics public. With a $2.5 billion pre-money valuation on the table, >$300 million in multi-year orders disclosed and a sizable $620M+ financing tied to the deal, CCXI offers concentrated upside if Digit's commercial rollout scales. This trade idea lays out an entry, stop, targets…
Skydance's upcoming theatrical release 'Impossible Mission' and its planned spin-off architecture create a clear path to multiple revenue streams — box office, streaming licensing, TV/games spin-offs and merchandising. This is a speculative, high-risk trade: buy a starter position with strict sizing and a firm stop while watching opening weekend, c…
Taboola (TBLA) offers a low multiple, significant free cash flow and an EV/EBITDA near 4. That combination makes a mid-term long worth considering despite an active class-action overhang and elevated short activity. Entry at $3.45, stop $2.80, target $5.25 — horizon: mid term (45 trading days).
Ally beat on key operational objectives in Q3: higher-yielding loan growth, improving capital returns, and intact credit metrics. The stock trades below recent highs on a pullback; fundamentals and valuation leave room for a re-rate. This is a mid-term trade idea with clear entry, stop, and target.
Equifax (EFX) beat Q3 estimates with $1.69B revenue and $2.26 EPS, while management trimmed 2026 revenue guidance on weak mortgage activity. Recent wins - including a $550M annual government contract and faster VantageScore adoption - plus AI efficiency gains argue for re-rating from today’s ~$20.7B market cap. This is a tactical long thesis: entry…
FEIM's recent pullback has left the stock below key moving averages and trading with an oversold RSI, but fundamentals - a $71M backlog, clean balance sheet and fresh capital from a July offering - argue for a mid-term rebound. This trade idea lays out entry, stop and target levels with a 45-trading-day horizon.
Array Technologies (ARRY) carries a large orderbook, but a mismatch between booked revenue and cash conversion, weakening top-line trends and heavy short interest make the shares a high-risk short. Trade plan: short at $3.35, stop $4.00, target $2.20 over a mid term (45 trading days) horizon.
<p>Gladstone Investment (GAIN) trades at a sub-1.0 price-to-book, yields roughly 6.4% and is showing signs of NAV recovery as floating-rate assets benefit from higher rates. That combination makes it attractive for an income-oriented tactical long, but the position comes with outsized credit and liquidity risk for a small-cap BDC. This trade lays o…
Harmony Biosciences (HRMY) runs a predictable commercial engine with WAKIX generating steady growth and outsized free cash flow. The shares trade at a modest multiple for a single-product commercial-stage drugmaker, giving a favorable risk-reward on dips. That said, an imminent patent ruling is a binary event that can rapidly reprice the stock. The…
